About Alexza
Alexza is a company based in Mountain View (United States) founded in 2000. Alexza has raised $97 million across 8 funding rounds from investors including T. Rowe Price, Frazier Healthcare Partners and Abingworth. Alexza offers products and services including Staccato Technology and Adasuve. Alexza operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, MannKind Corp, Neurocrine and PTC Therapeutics, among others.
- Headquarter Mountain View, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alexza Pharmaceuticals
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$97 M (USD)
in 8 rounds
-
Latest Funding Round
$5 M (USD), Post-IPO
Feb 24, 2016
-
Investors
T. Rowe Price
& 13 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alexza
Alexza offers a comprehensive portfolio of products and services, including Staccato Technology and Adasuve.
Handheld inhaler for rapid systemic drug delivery to treat medical conditions.
Treatment for agitation in schizophrenia or bipolar disorder via inhalation.
Funding Insights of Alexza
Alexza has successfully raised a total of $97M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in February 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $5.0M
-
First Round
First Round
(01 Sep 2002)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2016 | Amount | Post-IPO - Alexza | Valuation |
investors |
|
| Sep, 2015 | Amount | Post-IPO - Alexza | Valuation |
investors |
|
| Oct, 2014 | Amount | Post-IPO - Alexza | Valuation |
investors |
|
Investors in Alexza
Alexza has secured backing from 14 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include T. Rowe Price, Frazier Healthcare Partners and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in the US
|
Founded Year | Domain | Location | |
|
Investments are made in life sciences firms across all stages.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alexza
Financial Statements - Alexza
Alexza Comparisons
Competitors of Alexza
Alexza operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, MannKind Corp, Neurocrine and PTC Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Latest news on Alexza
Frequently Asked Questions about Alexza
Alexza was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Alexza is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Alexza is a funded company, having raised a total of $97M across 8 funding rounds to date. The company's 1st funding round was a Post-IPO of $8M, raised on Sep 01, 2002.
Founded in 2000, Alexza is engaged in the biotechnology sector, focusing on the development of inhalation-based therapeutics for acute and intermittent conditions. Proprietary Staccato system technology is utilized to vaporize drug compounds for delivery through deep lung inhalation. Key products include treatments for migraine, panic attacks, breakthrough pain, and acute agitation in schizophrenia patients. Operations are based in Mountain View, United States.
Alexza's top competitors include Jazz Pharmaceuticals, MannKind Corp and PTC Therapeutics.
Alexza offers Staccato Technology and Adasuve.
Alexza has 14 investors. Key investors include T. Rowe Price, Frazier Healthcare Partners, Abingworth, Burrill and Company, and Alloy Ventures.